2025-11-16 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX) based on the data you provided. I've included numerical summaries, comparisons to the S&P 500 (VOO), and key points from the news and financial data.

**Report on Recursion Pharmaceuticals (RXRX)**

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop drugs.

**1. Performance vs. S&P 500 (VOO)**

*   **RXRX Cumulative Return:** -33.31%
*   **VOO Cumulative Return:** 40.59%
*   **Relative Divergence:**
    *   Current: -60.1
    *   Range: Max (84.1), Min (-64.3)
    *   Relative Position: 2.8 (Indicates RXRX is near the bottom of its historical relative performance range compared to VOO)

**Analysis of Alpha, Beta, CAGR, MDD**

| Year       | CAGR  | MDD   | Alpha | Beta  | Cap(B) |
| :----------- | :---- | :---- | :------ | :---- | :----- |
| 2021-2023  | 22.0% | 81.0% | 26.0% | -0.1 | 5.4  |
| 2022-2024  | 11.0% | 81.0% | -10.0% | 0.1 | 3.7  |
| 2023-2025  | 9.0%  | 80.0% | -54.0% | 0.1 | 2.3  |

*   **CAGR Trend:** The Compound Annual Growth Rate (CAGR) is decreasing over the periods analyzed, suggesting slowing growth.
*   **MDD (Maximum Drawdown):** Consistently high MDD values (around 80%) indicate significant potential for loss.
*   **Alpha:** Alpha has deteriorated significantly from positive (26%) to negative (-54%), indicating underperformance relative to the benchmark.
*   **Beta:** Beta values close to 0 suggest RXRX's price is weakly correlated with the market (S&P 500).
*   **Cap:**  decreasing Cap(B) indicates that the company has less capitalization than previous years.

**2. Recent Stock Price Movement**

*   **Current Price:** 4.14
*   **Previous Close:** 4.33
*   **Change:** -4.39%
*   **5-Day Moving Average:** 4.468
*   **20-Day Moving Average:** 5.327
*   **60-Day Moving Average:** 5.1691

**Analysis:** The current price is below all moving averages, suggesting a downtrend.  The -4.39% change from the previous close indicates a significant recent drop, which may be tied to recent news events.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommendation)
*   **RSI:** 7.81 (Oversold - typically indicates potential for a rebound)
*   **PPO:** -3.03 (Negative - Suggests a downtrend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (195 shares - Very Safe - MRI:0.90) Monthly invest 1.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Recent (20-day) Relative Divergence Change:** -6.4 (Indicates recent underperformance relative to the benchmark)
*   **Expected Return:** -163.1% (Significant projected underperformance vs. S&P 500 over a 2+ year investment horizon)

**Analysis:** The RSI indicates the stock may be oversold in the short term. The negative PPO and divergence change confirm the downtrend. Despite the MRI suggesting a medium investment, the very negative expected return is concerning and suggests significant risk.
The hybrid signal recommends investing 100% cash as a safe approach.

**4. Recent News & Significant Events**

*   **Key Themes:**
    *   **AI in Drug Discovery:** News highlights Recursion's AI focus but also suggests potential alternatives.
    *   **Leadership Change:** New CEO appointment.
    *   **Financial Performance:** Mixed reports of widening losses despite revenue growth. Q3 loss was narrower than expected, but revenue missed estimates.

**Analysis:** The news is mixed. The new CEO could bring strategic changes. However, recurring themes of widening losses are a concern, even with revenue growth. The Motley Fool article suggesting alternatives to Recursion is noteworthy.

**4-2. Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 2.62 (Hold)
*   **Target Price:** 6.33 (Average), 10.00 (High), 3.00 (Low)

**Analysis:** The analyst consensus is "Hold," suggesting a neutral outlook. The average target price of $6.33 indicates potential upside from the current price, but the low target of $3.00 implies significant downside risk as well.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
| :--------- | :---- | :-------- |
| 2025-11-05 | -0.36 | 0.01 B$   |
| 2025-08-05 | -0.41 | 0.02 B$   |
| 2025-05-05 | -0.5  | 0.01 B$   |
| 2024-11-06 | -0.34 | 0.03 B$   |
| 2025-11-05 | -0.34 | 0.03 B$   |

**Analysis:** EPS (Earnings Per Share) is consistently negative, indicating losses. Revenue is volatile and generally low.

**6. Financial Information**

Revenue and Profitability:

| Quarter      | Revenue   | Profit Margin |
| :----------- | :-------- | :-------------- |
| 2025-09-30 | $0.00B    | -194.74%       |
| 2025-06-30 | $0.02B    | -5.54%         |
| 2025-03-31 | $0.01B    | -47.31%         |
| 2024-12-31 | $0.00B    | -183.62%       |
| 2024-09-30 | $0.03B    | 53.69%         |

Capital and Profitability:

| Quarter      | Equity   | ROE      |
| :----------- | :------- | :------- |
| 2025-09-30 | $1.05B   | -15.50% |
| 2025-06-30 | $0.92B   | -18.70% |
| 2025-03-31 | $0.93B   | -21.68% |
| 2024-12-31 | $1.03B   | -17.29% |
| 2024-09-30 | $0.52B   | -18.27% |

**Analysis:**
*   **Revenue:** Revenue is inconsistent and sometimes negligible.
*   **Profit Margin:** Profit margins are generally negative, indicating the company is not profitable.
*   **Equity:** Equity is relatively stable.
*   **ROE (Return on Equity):** ROE is negative, reflecting the company's inability to generate profits from equity.

**7. 종합 분석 (Overall Analysis)**

Recursion Pharmaceuticals (RXRX) presents a high-risk investment opportunity.

*   **Poor Performance:** Significantly underperforming the S&P 500.
*   **Financial Concerns:** Consistent losses, negative profit margins, and negative ROE raise serious questions about the company's financial sustainability.
*   **Mixed Signals:**  The company's potential lies in its AI-driven drug discovery platform. However, it faces strong headwinds, including widening losses, and increased competition.
*   **Downtrend:** Recent price action indicates a downtrend.
*   **Analyst Sentiment:** Neutral analyst ratings.
*   **Key Positives:**  New CEO appointment, which could bring positive strategic changes. The company's focus on AI could provide long-term value if successful.

**Recommendation:** Due to the significant financial risks and negative performance, caution is advised. A potential investor should carefully consider their risk tolerance. Although the RSI suggests the stock may be oversold, the fundamental financial concerns are substantial.
